Our Experts in the News
-
‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval
June 16, 2021
STAT
-
New Alzheimer's drug approval fallout: Public Citizen seeks removal of FDA's Woodcock, Cavazzoni and Dunn
June 16, 2021
Endpoints News
-
Public Citizen calls for top FDA officials to resign following Alzheimer's drug approval
June 16, 2021
Biopharma Dive
-
Watchdog Group Demands Removal of FDA Leaders After Aducanumab Approval
June 16, 2021
Medscape
-
FDA Approves Controversial Alzheimer’s Treatment
June 14, 2021
POZ
-
FDA’s New CDER Director Grants Approval of Yet Another Expensive, Scientifically Questionable Drug ... More Will Follow.
June 11, 2021
Forbes
-
FDA approves Biogen’s $56,000 drug for Alzheimer’s
June 9, 2021
Industry Leaders
-
Biogen’s $56,000-a-year Alzheimer’s drug reignites US debate over costs
June 8, 2021
Financial Times
-
Hospitals in medical study tested epilepsy drugs without telling patients
June 8, 2021
The Atlanta Journal Constitution
-
States, Medical Regulators and Institutions Must Act to End Physician Sexual Abuse
June 8, 2021
Ms. Magazine
-
A Highly Controversial Alzheimer’s Treatment Won FDA Approval. Scientists Say We Don’t Know If It Actually Works.
June 7, 2021
BuzzFeed News
-
FDA Defends Approval of Controversial Alzheimer's Drug
June 7, 2021
HealthDay
-
FDA's 'intellectually insulting' aducanumab decision opens up a regulatory foothold for leading competitors
June 7, 2021
Fierce Biotech
-
Sunrise stem cell clinic loses appeal of ruling stopping unapproved treatments
June 3, 2021
South Florida Sun-Sentinel
-
F.D.A. Approves Pricey Pill to Treat Vaginal Yeast Infections
June 2, 2021
The New York Times
-
Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored
May 28, 2021
The Cancer Letter
-
'A hugely consequential decision:' How Biogen's Alzheimer's drug came to face the FDA
May 27, 2021
BioPharma Dive
-
Mind Game
May 23, 2021
Full Measure
-
Did the U.S. FDA Improperly Expedite Remdesivir’s Approval? The Public Citizen Demand Letter to FDA, Plus a TrialSite Perspective
May 22, 2021
TrialSite News
-
FDA reviewers: Why we are against approval of aducanumab for Alzheimer's
May 5, 2021
Medscape
Login
Subscribe